

Frank M Rueemmele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/273334/publications.pdf>

Version: 2024-02-01

42
papers

2,336
citations

331670

21
h-index

289244

40
g-index

44
all docs

44
docs citations

44
times ranked

3054
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Use of Anti-Tumor Necrosis Factor Following the Implementation of the ECCO-ESPGHAN Guidelines and its Impact on the Outcome of Pediatric Crohn's Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 74, 79-84.	1.8	2
2	The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SET Quality Safety Registry. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 695-707.	1.3	14
3	Pediatric Prescriptions of Proton Pump Inhibitors in France (2009-2019): A Time-Series Analysis of Trends and Practice Guidelines Impact. <i>Journal of Pediatrics</i> , 2022, 245, 158-164.e4.	1.8	14
4	Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1243-1254.	1.3	18
5	High impact of pediatric inflammatory bowel disease on caregivers' work productivity and daily activities: an international prospective study. <i>Journal of Pediatrics</i> , 2022, , .	1.8	2
6	UNC45A deficiency causes microvillus inclusion disease-like phenotype by impairing myosin V-dependent apical trafficking. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	9
7	Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. <i>Journal of Clinical Immunology</i> , 2021, 41, 185-193.	3.8	15
8	Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1679-1685.	1.3	14
9	Intestinal immunoregulation: lessons from human mendelian diseases. <i>Mucosal Immunology</i> , 2021, 14, 1017-1037.	6.0	9
10	Bi-allelic variants in IPO8 cause a connective tissue disorder associated with cardiovascular defects, skeletal abnormalities, and immune dysregulation. <i>American Journal of Human Genetics</i> , 2021, 108, 1126-1137.	6.2	14
11	Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 616-627.	8.1	33
12	Mevalonate Kinase Deficiency: A Cause of Severe Very-Early-Onset Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1853-1857.	1.9	11
13	Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment. <i>JMIR Formative Research</i> , 2021, 5, e13888.	1.4	0
14	Congenital Diarrhea and Cholestatic Liver Disease: Phenotypic Spectrum Associated with MYO5B Mutations. <i>Journal of Clinical Medicine</i> , 2021, 10, 481.	2.4	20
15	Clinical Remission and Psychological Management are Major Issues for the Quality of Life in Pediatric Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 74-79.	1.8	3
16	Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. <i>Gut</i> , 2020, 69, 32-41.	12.1	37
17	Loss-of-Function Mutation in PTPN2 Causes Aberrant Activation of JAK Signaling Via STAT and Very Early Onset Intestinal Inflammation. <i>Gastroenterology</i> , 2020, 159, 1968-1971.e4.	1.3	20
18	Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course. <i>BMJ Open</i> , 2020, 10, e034892.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort. <i>Molecular Genetics and Metabolism Reports</i> , 2020, 23, 100581.	1.1	12
20	International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study. <i>BMJ Open</i> , 2020, 10, e035538.	1.9	0
21	Nutritional interventions for the treatment of IBD: current evidence and controversies. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481989053.	3.2	36
22	Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, 676-683.	1.8	11
23	Mucosal Healing and Bacterial Composition in Response to Enteral Nutrition Vs Steroid-based Induction Therapyâ€”A Randomised Prospective Clinical Trial in Children With Crohnâ€™s Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 846-855.	1.3	82
24	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 775-778.e6.	2.9	28
25	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1036-1049.e5.	2.9	233
26	Diagnostic Yield of Next-generation Sequencing in Very Early-onset Inflammatory Bowel Diseases: A Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1104-1112.	1.3	68
27	Management of Paediatric Ulcerative Colitis, Part 1. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 67, 257-291.	1.8	292
28	Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, 1901-1914.e3.	1.3	180
29	Atypical Manifestation of LPS-Responsive Beige-Like Anchor Deficiency Syndrome as an Autoimmune Endocrine Disorder without Enteropathy and Immunodeficiency. <i>Frontiers in Pediatrics</i> , 2016, 4, 98.	1.9	18
30	Use of Placebo in Pediatric Inflammatory Bowel Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 62, 183-187.	1.8	33
31	Outcome of home parenteral nutrition in 251 children over a 14-y period: report of a single center. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 1327-1336.	4.7	99
32	The localisation of the apical Par/Cdc42 polarity module is specifically affected in microvillus inclusion disease. <i>Biology of the Cell</i> , 2016, 108, 19-28.	2.0	31
33	Celiac disease in children. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 544-551.	1.5	41
34	Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. <i>Gut</i> , 2015, 64, 438-446.	12.1	72
35	Enteral Nutrition as Treatment Option for Crohn's Disease: In Kids Only?. <i>Nestle Nutrition Institute Workshop Series</i> , 2014, 79, 115-123.	0.1	12
36	Characterization of Crohn disease in X-linked inhibitor of apoptosisâ€”deficient male patients and female symptomatic carriers. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1131-1141.e9.	2.9	101

#	ARTICLE	IF	CITATIONS
37	Efficacy of Infliximab in Pediatric Crohn's Disease: A Randomized Multicenter Open-Label Trial Comparing Scheduled to On Demand Maintenance Therapy. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 388-394.	1.9	99
38	MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity. <i>Nature Genetics</i> , 2008, 40, 1163-1165.	21.4	321
39	Clinical and molecular aspects of autoimmune enteropathy and immune dysregulation, polyendocrinopathy autoimmune enteropathy X-linked syndrome. <i>Current Opinion in Gastroenterology</i> , 2008, 24, 742-748.	2.3	42
40	Microvillous inclusion disease (microvillous atrophy). <i>Orphanet Journal of Rare Diseases</i> , 2006, 1, 22.	2.7	123
41	Characteristics of Inflammatory Bowel Disease With Onset During the First Year of Life. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 43, 603-609.	1.8	106
42	Autoimmune enteropathy: molecular concepts. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 587-591.	2.3	56